Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment.
Webster
G J M
GJ
Kurtovic
J
J
Singh-Grewal
I
I
Friedlander
M
M
Riordan
S M
SM
D000111:Acetylcysteine / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008175:Lung Neoplasms; D008545:Melanoma / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000975:Antioxidants; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine; D000111:Acetylcysteine